Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Cash from Operations: 2009-2025

Historic Cash from Operations for Cytokinetics (CYTK) over the last 17 years, with Sep 2025 value amounting to -$107.5 million.

  • Cytokinetics' Cash from Operations fell 5.91% to -$107.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$433.0 million, marking a year-over-year decrease of 7.08%. This contributed to the annual value of -$395.9 million for FY2024, which is 4.45% up from last year.
  • As of Q3 2025, Cytokinetics' Cash from Operations stood at -$107.5 million, which was up 16.20% from -$128.3 million recorded in Q2 2025.
  • In the past 5 years, Cytokinetics' Cash from Operations ranged from a high of -$26.8 million in Q1 2022 and a low of -$131.6 million during Q1 2025.
  • Moreover, its 3-year median value for Cash from Operations was -$107.5 million (2025), whereas its average is -$107.1 million.
  • In the last 5 years, Cytokinetics' Cash from Operations crashed by 369.85% in 2021 and then increased by 24.60% in 2023.
  • Over the past 5 years, Cytokinetics' Cash from Operations (Quarterly) stood at -$44.7 million in 2021, then plummeted by 119.48% to -$98.2 million in 2022, then rose by 24.60% to -$74.0 million in 2023, then rose by 11.42% to -$65.6 million in 2024, then dropped by 5.91% to -$107.5 million in 2025.
  • Its last three reported values are -$107.5 million in Q3 2025, -$128.3 million for Q2 2025, and -$131.6 million during Q1 2025.